German company BioNTech and its US partner Pfizer announced on Monday that early results from ongoing Phase III trials showed that their vaccine was 90% effective in preventing COVID-19 infections. The statement from the two companies is the first release of successful data from a large-scale trial of coronavirus vaccines. According to their reports, they found no serious safety concern connected with the vaccine. Researchers believe the immunizing effects will not be short-lived. If substantiated, the Pfizer and BioNTech vaccine would be a breakthrough in the fight against the coronavirus pandemic.
German company BioNTech and Pfizer announce 90% effictive coronavirus vaccine | COVID-19 Special
